The 36-month beta value for CRGX is at 0.33. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for CRGX is 32.48M, and currently, shorts hold a 7.22% of that float. The average trading volume for CRGX on June 12, 2025 was 767.46K shares.
CRGX) stock’s latest price update
CARGO Therapeutics Inc (NASDAQ: CRGX)’s stock price has dropped by -2.18 in relation to previous closing price of 4.59. Nevertheless, the company has seen a loss of -1.32% in its stock price over the last five trading days. globenewswire.com reported 2025-03-18 that – Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value – – CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 – – Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination – SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).
CRGX’s Market Performance
CARGO Therapeutics Inc (CRGX) has seen a -1.32% fall in stock performance for the week, with a 10.32% gain in the past month and a 8.19% surge in the past quarter. The volatility ratio for the week is 3.03%, and the volatility levels for the past 30 days are at 2.21% for CRGX. The simple moving average for the past 20 days is 5.02% for CRGX’s stock, with a -60.94% simple moving average for the past 200 days.
Analysts’ Opinion of CRGX
Truist, on the other hand, stated in their research note that they expect to see CRGX reach a price target of $7, previously predicting the price at $32. The rating they have provided for CRGX stocks is “Hold” according to the report published on January 30th, 2025.
Piper Sandler gave a rating of “Neutral” to CRGX, setting the target price at $4 in the report published on January 30th of the current year.
CRGX Trading at 4.76% from the 50-Day Moving Average
After a stumble in the market that brought CRGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.36% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRGX starting from Radhakrishnan Anup, who sale 27,404 shares at the price of $3.84 back on May 14 ’25. After this action, Radhakrishnan Anup now owns 122,413 shares of CARGO Therapeutics Inc, valued at $105,272 using the latest closing price.
Radhakrishnan Anup, the See Remarks of CARGO Therapeutics Inc, sale 1,629 shares at $4.00 during a trade that took place back on Apr 03 ’25, which means that Radhakrishnan Anup is holding 77,317 shares at $6,522 based on the most recent closing price.
Stock Fundamentals for CRGX
The total capital return value is set at -0.76. Equity return is now at value -65.94, with -55.12 for asset returns.
Based on CARGO Therapeutics Inc (CRGX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -4.84.
Currently, EBITDA for the company is -160.43 million with net debt to EBITDA at 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.30.
Conclusion
In conclusion, CARGO Therapeutics Inc (CRGX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
